Effectiveness of Rituximab With Corticosteroids Versus Standard Oral Corticosteroids Plus Azathioprine in Participants With Moderate-to-Severe Pemphigus Vulgaris: A Quasi-Experimental Study

Pemphigus vulgaris is a rare but serious autoimmune disease in which the body's immune system produces antibodies that attack proteins (desmogleins) responsible for holding skin and mucosal cells together. This leads to painful blisters and erosions on the skin and mucous membranes, particularly in the mouth. If not treated effectively, the condition can cause significant morbidity and, in severe cases, life-threatening complications.

For many years the standard approach has involved high-dose oral corticosteroids combined with an immunosuppressive agent such as azathioprine. While this combination can control the disease, prolonged use of corticosteroids frequently results in serious adverse effects, including diabetes, osteoporosis, increased susceptibility to infections, and Cushingoid features. These complications often limit the long-term safety of conventional therapy.

Rituximab is a monoclonal antibody that specifically targets CD20-positive B-cells, the cells responsible for producing the harmful autoantibodies. By depleting these cells, rituximab addresses the underlying immunological mechanism of the disease more selectively than broad immunosuppression. Growing evidence from international studies suggests that rituximab, when used with a short course of corticosteroids, can achieve higher rates of sustained remission, reduce the frequency of relapses, and substantially lower the total amount of corticosteroids patients need to take.

Despite these promising findings, comparative data from Pakistan and similar resource-constrained settings remain limited. Cost, availability, and local clinical experience still influence treatment choices. A quasi-experimental design is therefore appropriate: patients with moderate to severe disease will be assigned to one of two treatment arms according to clinical suitability, affordability, and informed preference rather than by randomisation. One group will receive rituximab plus corticosteroids; the other will receive the conventional regimen of oral corticosteroids plus azathioprine.

Patients will be followed for twelve months. The primary focus will be the proportion of patients who achieve complete clinical remission. Secondary measures will include the time required to achieve disease control, the number and timing of relapses, the cumulative dose of corticosteroids administered, and the frequency and severity of treatment-related adverse events. Disease activity will be monitored using the Pemphigus Disease Area Index (PDAI) at regular intervals.